close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dermata Therapeutics, Inc. - Common Stock (NQ:DRMA)

0.7640 +0.0021 (+0.28%)
Delayed Quote Updated: 4:00 PM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Dermata Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Dermata Therapeutics Highlights Media Recognition of Tome Skincare Following Commercial Launch
- Tome Skincare featured in Cosmopolitan, Women's Wear Daily, AIR MAIL, and Thingtesting highlights Tome's growing recognition among leading beauty editors - 
From Dermata Therapeutics
Via ACCESS Newswire
News headline image
Dermata Advances Second Tome Skincare Product Toward Expected 2027 Launch with Initiation of Acne Clinical Trial
- Tome Clearing Treatment is Dermata's second once-weekly skincare product under its Tome brand - - Tome Clearing Treatment includes a salicylic acid wipe with Dermata's Bioneedle ™ mask and is... 
From Dermata Therapeutics
Via ACCESS Newswire
News headline image
Stocks to Watch: WETO, PRSO, DRMA, SNES Highlight Robotics, Defense, Skincare and Revenue Growth
Via AB Newswire
Topics Artificial Intelligence
News headline image
Graphene Manufacturing (OTCQX: GMGMF) Reports Battery Energy Density Gains
Via AB Newswire
Topics Artificial Intelligence
News headline image
Dermata Therapeutics Announces Positive Topline Results from Cosmetic Study Evaluating Its Tome Foundational Treatment
- Once-weekly Tome Foundational Treatment demonstrated improvements across key measures of skin appearance after four treatments - - Over 71% of study participants were graded as having overall... 
From Dermata Therapeutics
Via ACCESS Newswire
News headline image
Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment
From Dermata Therapeutics
Via ACCESS Newswire
News headline image
Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch
From Dermata Therapeutics
Via ACCESS Newswire
News headline image
Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
From Dermata Therapeutics
Via ACCESS Newswire
News headline image
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026
From Dermata Therapeutics
Via ACCESS Newswire
News headline image
Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment
From Dermata Therapeutics
Via ACCESS Newswire
News headline image
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026
Via ACCESS Newswire
News headline image
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System
Via ACCESS Newswire
News headline image
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025
Via ACCESS Newswire
News headline image
Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing
Via ACCESS Newswire
News headline image
Dermata Opens a New Chapter with the Release of Tome Skincare
Via ACCESS Newswire
News headline image
Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office
Via ACCESS Newswire
News headline image
Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Via ACCESS Newswire
News headline image
Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Via ACCESS Newswire
News headline image
A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity
Via ACCESS Newswire
News headline image
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Via ACCESS Newswire
News headline image
Dermata Announces Acceptance of Patent Application for Next-Generation Acne Treatment by Australian Patent Office
Via ACCESS Newswire
News headline image
Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Dermata Therapeutics Announces Presentation of Abstract at the European Academy of Dermatology and Venereology Congress 2025
Via ACCESS Newswire
News headline image
Life Science Virtual Investor Forum Agenda Announced for September 18th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Dermata Therapeutics to Present at the Life Sciences Virtual Investor Forum September 18th
Dermata invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care Treatments
Via ACCESS Newswire
News headline image
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Via ACCESS Newswire
News headline image
Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for Hyperhidrosis
Via ACCESS Newswire
News headline image
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
Via ACCESS Newswire
News headline image
Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks
Via ACCESS Newswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.